PitchSend

Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 56 Novo Nordisk increased market share in long-acting insulin and sustained leadership in fast-acting and premix insulin Long-acting insulin¹ volume market share across regions Novo Nordisk Fast-acting insulin² volume market share across regions North America Operations Region China Premix insulin³ volume market share across regions Region AAMEO Region Latin America 80% 70% 60% 50% 40% 30% 20% 10% 0% Aug 2013 80% 70% 60% 50% 40% 30% 20% 10% 0% Aug 2018 Aug 2013 Region Europe Region Japan & Korea 80% 70% 60% 50% 40% 30% 20% 10% 0% Aug 2018 Aug 2013 Aug 2018 1 Long-acting insulin comprises: TresibaⓇ, Levemir®, XultophyⓇ and Insulatard® (basal human insulin). Please note that not all products are launched in all markets 2 Short-acting insulin includes: Fiasp®, NovoLog® and ActrapidⓇ (bolus human insulin). Please note that not all products are launched in all markets 3 Premix insulin includes: Ryzodeg®, NovoMixⓇ and MixtardⓇ 30 (premix human insulin). Please note that not all products are launched in all markets Source: IQVIA monthly MAT Aug, 2018 volume figures AAMEO: Africa, Asia, Middle-East and Oceania novo nordisk

View entire presentation